EloraTZP in 2026: Lilly's Amylin-Tirzepatide Combo Posts 23% Weight Loss in New Trial

According to Lilly's press release, the Phase 2b trial enrolled 367 adults in the U.S. and Argentina who had type 2 diabetes along with obesity or overweight. Participants were randomized to eloralintide alone, tirzepatide 15 mg alone, one of four eloraTZP combination doses, or placebo, for 48 weeks.

Tirzepatide is already a dual GIP/GLP-1 receptor agonist. Eloralintide works on a different pathway: it mimics amylin, a pancreatic hormone that slows stomach emptying and signals fullness to the brain. The idea behind eloraTZP is that stacking an amylin agonist on top of tirzepatide produces more weight loss than either mechanism alone — and in this trial, it did.

The results, as reported by Lilly and covered by HCPLive, break down like this. From an average starting weight of about 232 pounds:

• Tirzepatide 15 mg alone: −14.8% (about 34 pounds)
• EloraTZP, eloralintide 6 mg + tirzepatide 5 mg: −19.4% (about 45 pounds)
• EloraTZP, eloralintide 6 mg + tirzepatide 10 mg: −19.9% (about 46 pounds)
• EloraTZP, eloralintide 9 mg + tirzepatide 15 mg: −23.3% (about 54 pounds)
• Placebo: −3.0%

Two things stand out. First, even the middle combination doses — using only 5 or 10 mg of tirzepatide — beat full-dose tirzepatide 15 mg. Second, 23.3% weight loss in a type 2 diabetes population is remarkable, because people with diabetes consistently lose less weight on these medications than people without it. For context, tirzepatide produced about 15% weight loss in its own diabetes trial arms, and these new combination numbers approach what the strongest injectables achieve in patients without diabetes.

Blood sugar control improved too. A1C fell by 2.2 to 2.9 percentage points across the eloraTZP doses, from a baseline of roughly 8.1%, compared with 2.4 points for tirzepatide alone.

No Phase 2 readout is complete without the safety column. The most common adverse events were gastrointestinal — nausea, vomiting, and related symptoms — and Lilly described them as generally mild to moderate, which is the familiar profile for this drug class.

Discontinuation due to adverse events is where the trade-off shows: 10.8% to 27.0% of participants on eloraTZP stopped treatment because of side effects, compared with 2.9% on tirzepatide alone. More weight loss came with more people who could not tolerate the regimen, especially at higher doses. That matters in the real world, where staying on a medication long enough to benefit is half the battle. It is also why slow dose titration and proactive nausea management — like the anti-nausea support JoeyMed offers alongside GLP-1 treatment — are part of responsible weight loss care today.

This was also a 367-person Phase 2b study, not a pivotal trial. Lilly says Phase 3 trials of eloraTZP are planned to begin in late 2026, which means an FDA decision is realistically years away.

EloraTZP joins a crowded race to improve on today's injectables. Novo Nordisk is developing CagriSema, its own amylin-plus-GLP-1 combination, and Lilly's triple agonist retatrutide posted its own striking results earlier this year. None of these are available yet.

What is available: tirzepatide itself — the comparator that still delivered roughly 15% weight loss in this trial — along with semaglutide. These remain the proven, FDA-regulated backbone of medical weight loss in 2026, and the new data is, if anything, a reminder of how effective they already are. JoeyMed offers provider-supervised tirzepatide through its TIRZ HD program, with dosing tailored to your response and tolerability.

There is no public pricing for eloraTZP, and there will not be until it nears approval. If a combination product launches, expect it to debut at or above current brand-name injectable prices, with insurance coverage lagging behind — the same pattern patients have seen with every new entrant in this class.

For most people, waiting years for a drug that may offer additional weight loss — with a higher chance of stopping due to side effects — makes less sense than starting an effective treatment now. The weight you lose over the next two years on tirzepatide is weight you are not carrying while the next generation moves through Phase 3. And because obesity treatment is long-term, patients who start today will have options if and when eloraTZP, CagriSema, or retatrutide reach the market.

GLP-1 medications are not for everyone. They are generally avoided in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, a history of pancreatitis, or during pregnancy, and the right dose depends on your health history. That is a conversation to have with a licensed provider, not a decision to make from headlines.

If the eloraTZP news has you thinking about treatment, you do not need to wait for 2028 to act on it. JoeyMed's weight loss program connects you with a licensed provider online who reviews your health history, determines whether GLP-1 therapy such as tirzepatide is appropriate for you, and builds a titration plan designed to keep side effects manageable. Medications ship directly to your door, and follow-ups happen on your schedule — no waiting rooms. Start your online visit today and find out whether today's proven options are the right fit while the next generation works its way through trials.